IMMUNOVANT, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMUNOVANT, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $543.61M.
- IMMUNOVANT, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $466.73M, a 564.60% increase year-over-year.
- IMMUNOVANT, INC. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $70.23M.
- IMMUNOVANT, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $200.00M.
- IMMUNOVANT, INC. stock issued during period, value, new issues for fiscal 2026 was $543.69M, a 20.91% increase from fiscal 2025.
- IMMUNOVANT, INC. stock issued during period, value, new issues for fiscal 2025 was $449.68M, a 3.65% decline from fiscal 2024.
- IMMUNOVANT, INC. stock issued during period, value, new issues for fiscal 2024 was $466.73M, a 564.60% increase from fiscal 2023.
- IMMUNOVANT, INC. stock issued during period, value, new issues for fiscal 2023 was $70.23M, a 64.89% decline from fiscal 2022.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $543.69M 10-K · filed 2026-05-20 | |
| 2025-12-31 | $543.61M 10-Q · filed 2026-02-06 | |
| 2025-03-31 | $449.68M 10-K · filed 2026-05-20 | |
| 2024-03-31 | $466.73M 10-K · filed 2026-05-20 | |
| 2023-12-31 | $466.73M 10-Q · filed 2025-02-06 | |
| 2023-03-31 | $70.23M 10-K · filed 2025-05-29 | |
| 2022-12-31 | $70.23M 10-Q · filed 2024-02-12 | |
| 2022-03-31 | $200.00M 10-K · filed 2023-05-22 | |
| 2021-09-30 | $200.00M 10-Q · filed 2023-02-03 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-02-16 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-02-16 | |
| 2018-12-31 | $9.77M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |